Favi 2009.

Methods	Design: open‐label RCT Duration: May 2004 to August 2006 Follow up: 3 years
Participants	Setting: single centre transplant unit Country: Italy Recipients of DD transplants Number (group 1/group 2): 60 (30/30) Mean age ± SD (years): group 1 (44 ± 11); group 2 (45 ± 10) Sex (M/F): group 1 (15/15); group 2 (18/12) Exclusions: PRA > 50%; cold ischaemia time > 24 hours
Interventions	Treatment group 1 (EVL/sCSA) EVL; start dose 0.75 mg twice/d then dosed to maintain a trough level of 3 to 12 ng/mL CSA: start dose 400 mg twice/d and then dosed to maintain a C2 level of 350 to 700 ng/mL Treatment group 2 (MMF/sTAC) TAC: dosed to maintain a trough level of 8 to 10 ng/mL by month 3 and 5 to 8 ng/mL thereafter MMF: 1 g twice daily Co‐interventions Basiliximab Corticosteroids
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with a functioning graft BPAR CrCl Biochemical adverse effects
Notes	Comparison: TOR‐I versus antimetabolite CSA and TAC were considered comparable across the groups as CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Quote: "consecutively assigned 1:1 to one of the two immunosuppressive regimens"
Allocation concealment (selection bias)	High risk	Quote: "consecutively assigned 1:1 to one of the two immunosuppressive regimens"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome was laboratory based and unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients completed follow‐up
Selective reporting (reporting bias)	High risk	Adverse effects incompletely reported
Other bias	Low risk	This study was partially supported by UCSC grant MIUR 2007